NOV - NOV Inc.
Connor Clark and Lunn Investment Management Ltd. acquired a new position in NOV Inc. (NYSE: NOV) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 44,430 shares of the oil and gas exploration company's stock, valued at
Nov Inc. (NOV) reported earnings 30 days ago. What's next for the stock?
Algert Global LLC trimmed its position in shares of NOV Inc. (NYSE: NOV) by 34.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 440,660 shares of the oil and gas exploration company's stock after selling 231,350 shares during the
HOUSTON, Aug. 19, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock, payable on September 25, 2026 to each stockholder of record on September 11, 2026. About NOV NOV delivers technology-driven solutions to empower the global energy industry.
NOV Inc. has outperformed the energy sector recently, driven by oil price leverage and higher financial beta. I see limited upside for NOV stock due to its premium valuation (23.0x P/E) versus peers and lack of a high-growth digital segment. NOV's deepwater and FPSO exposure is a double-edged sword; potential oil price declines could disproportionately impact its offshore business.
NOV, Oil States International and Natural Gas Services have been highlighted in this Industry Outlook article.
Edgestream Partners L.P. reduced its stake in shares of NOV Inc. (NYSE: NOV) by 18.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 132,431 shares of the oil and gas exploration company's stock after selling 29,162 shares during the period. Edgestream Partners L.P.'s holdings
Softer equipment demand and conservative capital spending by upstream players make the outlook for the Zacks Oil and Gas- Mechanical and Equipment industry gloomy. NOV, OIS and NGS are trying to survive industry challenges.
NOV's margin gains and record Energy Equipment profitability offset uneven revenues as backlog trends shape the second-half outlook.
NOV beats Q2 earnings and revenue estimates despite lower sales, as Energy Equipment strength, shareholder returns and upbeat Q3 guidance support momentum.
NOV NYSE: NOV reported second-quarter 2026 revenue of $2.13 billion and net income of $112 million, or $0.31 per diluted share, as operational improvements, favorable project execution and stronger deliveries supported results despite continued disruption in the Middle East.
Although the revenue and EPS for Nov Inc. (NOV) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NOV Inc. (NOV) Q2 2026 Earnings Call Transcript
Nov Inc. (NOV) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.29 per share a year ago.
Revenues of $2.13 billion, up 4% sequentially and down 2% year-over-year Net income of $112 million, or $0.31 per share, an increase of $93 million sequentially and $4 million year-over-year Adjusted EBITDA 1,2 of $283 million, an increase of $106 million sequentially and $31 million year-over-year Returned $127 million of capital to shareholders through share repurchases and dividends Bookings of $474 million, representing a book-to-bill of 74% 1 Free Cash Flow, Excess Free Cash Flow, Adjusted operating profit, and Adjusted EBITDA are non-GAAP measures, see “Non-GAAP Financial Measures,” and “Reconciliation of GAAP to non-GAAP measures” below. 2 Second quarter 2026 Adjusted EBITDA includes a benefit of approximately $40 million related to tariff refunds HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) today reported second quarter 2026 revenues of $2.13 billion, an increase of four percent sequentially and a decrease of two percent compared to the second quarter of 2025.
NOV faces a key Q2 test as delayed shipments, strong order trends and cost cuts collide with ongoing logistics and drilling headwinds.
Nov Inc. (NOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.